RAF signaling in neuroendocrine neoplasms: From bench to bedside

Cancer Treatment Reviews

Volumn 40, Issue 8, 2014, Pages 974-979

  Fazio, Nicola ^a   Abdel Rahman, Omar ^b   Spada, Francesca ^a   Galdy, Salvatore ^a   De Dosso, Sara ^c   Capdevila, Jaume ^d   Scarpa, Aldo ^e  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

BRAF; Cell signaling; MAPK; Molecular targeted therapy; NET; Neuroendocrine neoplasms; Neuroendocrine tumors; RAF; RAF 1

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CHIR 265; CHROMOGRANIN A; CYCLOPHOSPHAMIDE; DABRAFENIB; DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PASIREOTIDE; RAF PROTEIN; SEROTONIN; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; SUNITINIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CANCER GROWTH; CELL PROLIFERATION; GENE EXPRESSION; GENE MUTATION; HORMONE DETERMINATION; HUMAN; NEUROENDOCRINE TUMOR; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

BRAF; CELL SIGNALING; MAPK; MOLECULAR TARGETED THERAPY; NET; NEUROENDOCRINE NEOPLASMS; NEUROENDOCRINE TUMORS; RAF; RAF-1;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; RAF KINASES;

EID: 84904791071     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.06.009     Document Type: Review

References (56)

1. Ameri P., Ferone D. Diffuse endocrine system, neuroendocrine tumors and immunity: what's new?. Neuroendocrinology 2012, 95:267-276.
2. Yao J., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumours in 35,825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
3. Lawrence B., Gustafsson B.I., Chan A., Svejda B., Kidd M., Modlin I.M. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011, 40:1-18.
4. Bosman F, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. International Agency for Research on Cancer, Lyon; 2010.
5. Modlin I., Moss S., Chung D., Jensen R.T., Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumours. J Natl Cancer Inst 2008, 100:1282-1289.
6. Fazio N., Scarpa A., Falconi M. Molecular targeted therapies in enteropancreatic neuroendocrine tumors: from biology to clinical practice. Curr Med Chem 2014, 21:2017-2025.
7. Jiao Y., Shi C., Edil B.H., de Wilde R.F., Klimstra D.S., Maitra A., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331:1199-1203.
8. Missiaglia E., Dalai I., Barbi S., Beghelli S., Falconi M., della Peruta M., et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR path-way. J Clin Oncol 2010, 28:245-255.
9. Mordret G. MAP kinase kinase: a node connecting multiple pathways. Biol Cell 1993, 79:193-207.
10. L'Allemain G. Deciphering the MAP kinase pathway. Prog Growth Factor Res 1994, 5:291-334.
11. Niault T.S., Baccarini M. Target of RAf in tumorigenesis. Carcinogenesis 2010, 31:1165-1174.
12. Santen R.J., Song R.X., McPherson R., Kumar R., Adam L., Jeng M.H., et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002, 80:239-256.
13. Adjei A.A. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. Clin Lung Cancer 2005, 7:221-223.
14. De Luca A., Maiello M.R., D'Alessio A., Pergameno M., Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012, 16(Suppl. 2):S17-S27.
15. Bonner J.A., Vroman B.T., Christianson T.J., Kamitz L.M. Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells. Int J Radiat Oncol Biol Phys 1998, 42:921-925.
16. Lewis T.S., Shapiro P.S., Ahn N.G. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 7:49-139.
17. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22:153-183.
18. Vakiani E., Solit D. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011, 223:219-229.
19. Weber C.K., Slupsky J.R., Kalmes H.A., Rapp U.R. Active RAS induces heterodimerization of cRAF and BRAF. Cancer Res 2001, 61:3595-3598.
20. Rushworth L.K., Hindley A.D., O'Neill E., Kolch W. Regulation and role of RAF-1/B-RAF heterodimerization. Mol Cell Biol 2006, 26:2262-2272.
21. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
22. Hindley A., Kolch W. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of RAF kinases. J Cell Sci 2002, 115:1575-1581.
23. Huser M., Luckett J., Chiloeches A., Mercer K., Iwobi M., Giblett S., et al. MEK kinase activity is not necessary for RAF-1 function. EMBO J 2001, 20:1940-1951.
24. Marais R., Light Y., Paterson H.F., Mason C.S., Marshall C.J. Differential regulation of RAF-1, A-RAF, and B-RAF by oncogenic RAS and tyrosine kinases. J Biol Chem 1997, 272:4378-4383.
25. Emuss V., Garnett M., Mason C., Marais R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 2005, 65:9719-9726.
26. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
27. Hagemann C., Rapp U.R. Isotype-specific functions of RAF kinases. Exp Cell Res 1999 Nov 25, 253(1):34-46.
28. Tannapfel A., Vomschloss S., Karhoff D., Markwarth A., Hengge U.R., Wittekind C., et al. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumours. Am J Clin Pathol 2005 Feb, 123(2):256-260.
29. Perren A., Schmid S., Locher T., Saremaslani P., Bonvin C., Heitz P.U., et al. BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 2004, 11:855-860.
30. Beghelli S., Pelosi G., Zamboni G., Falconi M., Iacono C., Bordi C., et al. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol 1998, 186:41-50.
31. Kunnimalaiyaan M., Chen H. The RAF-1 pathway: a molecular target for treatment of select neuroendocrine tumours?. Anticancer Drugs 2006 Feb, 17(2):139-142.
32. Sippel R.S., Carpenter J.E., Kunnimalaiyaan M., Lagerholm S., Chen H. RAF-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2003 Aug, 285(2):G245-G254.
33. Vaccaro A., Chen H., Kunnimalaiyaan M. In-vivo activation of RAF-1 inhibits tumour growth and development in a xenogRAFt model of human medullary thyroid cancer. Anticancer Drugs 2006 Aug, 17(7):849-853.
34. Sippel R.S., Carpenter J.E., Kunnimalaiyaan M., Lagerholm S., Chen H. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2003, 285:G245-G254.
35. Ning L., Chen H., Kunnimalaiyaan M. Focal adhesion kinase, a downstream mediator of Raf-1 signaling, suppresses cellular adhesion, migration, and neuroendocrine markers in BON carcinoid cells. Mol Cancer Res 2010, 8:775-782.
36. Flaherty K.T. Sorafenib in renal cell carcinoma. Clin Cancer Res 2007, 13:747-752s.
37. Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95:581-586.
38. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004, 64.
39. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., et al. Discovery of a selective inhibitor of oncogenic B-RAF kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105:3041-3046.
40. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemuRAFenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
41. Ascierto P., Minor D., Ribas A., Lebbe C., O'Hagan A., Arya N., et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 10 Sep 2013, 31(26):3205-3211.
42. Cook M.R., Pinchot S.N., Jaskula-Sztul R., Luo J., Kunnimalaiyaan M., Chen H., et al. Identification of a novel RAF-1 pathway activator that inhibits gastrointestinal carcinoid cell growth. Mol Cancer Ther 2010 Feb, 9(2):429-437. [MCT-09-0718, Epub 2010 Jan 26]. 10.1158/1535-7163.
43. Pinchot S., Adler J., Luo Y., Ju J., Li W., Shen B., et al. Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the RAF-1 pathway. Am J Surg 2009, 197(3):313-319.
44. Adler J.T., Cook M., Luo Y., Pitt S.C., Ju J., Li W., et al. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3β. Mol Cancer Ther May 2010, 9:1482.
45. Van Gompel J.J., Kunnimalaiyaan M., Holen K., Chen H. ZM336372, a RAF-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumour cells. Mol Cancer Ther 2005 Jun, 4(6):910-917.
46. Chan J.A., Mayer R.J., Jackson N., Malinowski P., Regan E., Kulke M. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumours. Cancer Chemother Pharmacol 2013 May, 71(5):1241-1246. [Epub 2013 Mar 9]. 10.1007/s00280-013-2118-9.
47. Carracedo A1., Baselga J. Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle. 2008 Dec 15, 7(24):3805-3809. [Epub 2008 Dec 22].
48. Hobday T, Rubin J, Holen K, Picus J, Donehower R, Marschke R, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol (Meeting Abstracts) June 2007; vol. 25 [no. 18_suppl 4504].
49. Castellano D., Capdevila J., Sastre J., Alonso V., Llanos M., Garcia-Carbonero R., et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer 2013 Dec, 49(18):3780-3787. [Epub 2013 Sep 5]. 10.1016/j.ejca.2013.06.042.
50. Lam E.T., Ringel M.D., Kloos R.T., Prior T.W., Knopp M.V., Liang J., et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010 May 10, 28(14):2323-2330. [Epub 2010 Apr 5]. 10.1200/JCO.2009.25.0068.
51. Quintela-Fandino M., Krzyzanowska M., Duncan G., Young A., Moore M.J., Chen E.X., et al. In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours. Br J Cancer 2013 Apr 2, 108(6):1298-1305. [Epub 2013 Feb 14]. 10.1038/bjc.2013.64.
52. Zitzmann K., Rüden J., Brand S., Goke B., Lichtl J., Spottl G., et al. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 1 September 2010, 295(1):100-109.
53. Valentino J.D., Li J., Zaytseva Y.Y., Elliott V.A., Kim J.T., Harris J.W., et al. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors. Clin Cancer Res 2014 Mar 1, 20(5):1212-1222.
54. Rapp U.R., Goldsborough M.D., Mark G.E., Bonner T.I., Groffen J., Reynolds F.H., et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci USA 1983, 80:4218-4222.
55. Banck M.S., Kanwar R., Kulkarni A.A., Boora G.K., Metge F., Kipp B.R., et al. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest 2013, 123(6):2502-2508.
56. Papageorgis P., Cheng K., Ozturk S., Gong Y., Lambert A.W., Abdolmaleki H.M., et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 2011, 71(3):998-1008.